
Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Disease
NO LONGER ACCEPTING APPLICATIONS
Published on:
December 17, 2025
Sign-up Expiration:
Updated:
Locations:
Salisbury, NC
Dr. Rakesh Patel
Further characterizing the efficacy and safety profile of Nerandomilast on top of a broad range of immunosuppressants has been identifited as an important unmet need. Understanding the potential risk of infections is a focus and if informative for the safety profile in association with Nerandomilast use in patients commonly seen by rheumatologists. Nerandomilast is being developed to treat people with lung fibrosis.
The purpose of this study is to test a drug called Nerandomilast to see:
- How Nerandomilast affects the lungs.
- How Nerandomilast impacts breathing and coughing.
- If Nerandomilast affects the risk for infections.
ENDED





